Tuesday, 02 January 2024 12:17 GMT

Investornewsbreaks Heartbeam Inc. (NASDAQ: BEAT) Reports Narrower Q3 Net Loss, Advances Heart Attack Assessment Program


Date:

(MENAFN- Investor Brand Network) HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, reported financial and operational results for the third quarter ended Sept. 30, 2026. The company recorded a net loss of $3 million, or $0.05 per share, compared with a net loss of $5.3 million, or $0.15 per share, in the prior-year period. Operating expenses declined to $3.5 million from $5.3 million, while cash and cash equivalents totaled $6.1 million as of Sept. 30, 2026. HeartBeam also raised approximately $4 million in net proceeds during the fourth quarter through the date of the announcement, bringing pro forma cash to approximately $10.1 million. The company now expects full-year 2026 net operating cash outflow of $12 million to $12.5 million.

Operationally, HeartBeam advanced its strategic focus on heart attack assessment, receiving U.S. Food and Drug Administration (“FDA”) Breakthrough Device Designation and acceptance into the agency's Total Product Life Cycle Advisory Program (“TAP”). The company completed enrollment of 486 patients in its HEADSTART-ACS study and reported positive results from its 132-patient ALIGN-ACS pilot study, which demonstrated higher specificity than standard 12-lead electrocardiograms (“ECGs”) with comparable sensitivity. HeartBeam plans to finalize the design of its U.S. pivotal study in the fourth quarter of 2026 and begin patient enrollment in the first quarter of 2027.

To view the full press release, visit

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company's newsroom at

(1) Cleared Indications for Use

The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company's Cleared Indications for Use at for details on the intended use of its technology.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: /Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

MENAFN13112026000224011066ID1111958785


Investor Brand Network

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search